Prevention of tuberculosis in people living with HIV

Clinical Infectious Diseases

Volumn 50, Issue SUPPL. 3, 2010, Pages

  Granich, Reuben ^a   Akolo, Christopher ^b   Gunneberg, Christian ^a   Getahun, Haileyesus ^a   Williams, Phoebe ^a   Williams, Brian ^c  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b NATIONAL HEALTH SERVICE   (United Kingdom)

^c STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; ISONIAZID; PLACEBO; PYRAZINAMIDE; RIFAMPICIN; STAVUDINE;

ANTIVIRAL THERAPY; BEHAVIOR MODIFICATION; CLINICAL TRIAL; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEALTH PROGRAM; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; LIVER TOXICITY; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; NAUSEA; PATIENT COUNSELING; PERIPHERAL NEUROPATHY; PREVALENCE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SCREENING TEST; SHORT COURSE THERAPY; TUBERCULOSIS; VOMITING;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; COMMUNICABLE DISEASE CONTROL; HIV INFECTIONS; HUMANS; TUBERCULOSIS;

EID: 77951838895     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/651494     Document Type: Review

References (89)

1. World Health Organization. Global tuberculosis control : epidemiology, strategy, financing WHO report 2009. http://whqlibdoc.who.int/publications/2009/ 9789241598866-eng.pdf. Accessed 9 April 2010.
2. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999;282(7):677-686.
3. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2004(1): CD000171.
4. Getahun H, Gunneberg C, Granich R, Nunn P. HIV infection-associated tuberculosis: The epidemiology and the response. Clin Infect Dis 2009; 50(Suppl 3):S201-S207 (in this supplement).
5. Hanifa Y, Grant AD, Lewis J, Corbett EL, Fielding K, Churchyard G. Prevalence of latent tuberculosis infection among gold miners in South Africa, Int J Tuberc Lung Dis 2009; 13:39-46.
6. Castro KG. Tuberculosis as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis 1995;21(Suppl 1):S66-S71.
7. Chaisson RE, Martinson NA. Tuberculosis in Africa - combating an HIV-driven crisis. N Engl J Med 2008; 358(11):1089-1092.
8. Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992;326(4):231-235.
9. Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 2005; 191(2):150-158. (Pubitemid 40096371)
10. World Health Organization, global tuberculosis control: a short update to the 2009 report. December 2009. Geneva: World Health Organization, 2009. http://www.who.int/tb/publications/global-report/2009/update/tbu-9.pdf. Accessed 9 April 2010.
11. Saraceni V, King BS, Cavalcante SC, et al. Tuberculosis as primary cause of death among AIDS cases in Rio de Janeiro, Brazil, Int J Tuberc Lung Dis 2008; 12(7):769-772. (Pubitemid 351976707)
12. World Health Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Geneva: World Health Organization, 2008. http://www.who.int/hiv/pub/towards-universal-access-report-2008. pdfAccessed 9 April 2010.
13. UNAIDS Wa. Policy statement on preventive therapy against tuberculosis in people living with HIV: report of a meeting held in Geneva 18-20 February 1998. http://whqlibdocwhoint/HQ/1998/WHO-TB-98.255pdf. Accessed 9 April 2010.
14. Churchyard GJ, Scano F, Grant AD, Chaisson RE. Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities. J Infect Dis 2007; 196(Suppl 1):S52-S62. (Pubitemid 47206085)
15. Kochi A. Tuberculosis control - is DOTS the health breakthrough of the 1990s? World Health Forum 1997; 18:225-32; discussion 33-47.
16. Raviglione MC, Uplekar MW. WHO's new Stop TB Strategy. Lancet 2006;367(9514):952-955.
17. Allen S, Tice J, Van de Perre P, et al. Effect of serotesting with counselling on condom use and seroconversion among HIV discordant couples in Africa. BMJ 1992;304(6842):1605-1609.
18. World Health Organization. Essential prevention and care interventions for adults and adolescents living with HIV in resource-limited settings. Geneva: world Health Organization, 2008. http://www.who.int/hiv/pub/prev-care/OMS-EPP- AFF-en.pdf. Accessed 9 April 2010.
19. UNAIDS. Practical guidelines for intensifying HIV prevention - towards universal access. Geneva: UNAIDS. http://data.unaids.org/pub/ Manual/2007/jc1274-towardsuniversalaccess-en.pdf. Accessed 9 April 2010.
20. Piot P, Bartos M, Larson H, Zewdie D, Mane P. Coming to terms with complexity: a call to action for HIV prevention. Lancet 2008; 372(9641): 845-859.
21. Williams BG, Dye C. Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science 2003;301(5639):1535-1537. (Pubitemid 37128545)
22. Lawn SD, Myer L, Edwards D, Bekker LG, Wood R. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 2009;23:1717-1725.
23. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002;359(9323):2059-2064. (Pubitemid 34680968)
24. Antonucci G, Girardi E, Raviglione MC, Ippolito G. Risk factors for tuberculosis in HIV-infected persons: a prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). JAMA 1995;274(2):143-148.
25. Allen S, Batungwanayo J, Kerlikowske K, et al. Two-year incidence of tuberculosis in cohorts of HIV-infected and uninfected urban Rwandan women. Am Rev Respir Dis 1992; 146(6):1439-1444.
26. Attia S, Egger M, Müller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009;23:1397-1404.
27. Bunnell R, Ekwaru JP, Solberg P, et al. Changes in sexual behavior and risk of HlV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS 2006;20(1):85-92. (Pubitemid 41818118)
28. World Health Organization. Essential prevention and care interventions for adults and adolescents living with HIV in resource-limited settings. Geneva: World Health Organization, 2008. http://www.who.int/hiv/pub/prev-care/OMS-EPP- AFF-en.pdf. Accessed 9 April 2010.
29. World Health Organization. Interim policy on collaborative TB/HIV activities. Geneva: World Health Organization, 2004.
30. Bunnell R, EJ, Solberg P, et al. Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS 2006;20(1):85-92. (Pubitemid 41818118)
31. Joshi R, Reingold AL, Menzies D, Pai M. Tuberculosis among healthcare workers in low- and middle-income countries: a systematic review. PLoS Med 2006; 3(12):e494.
32. World Health Organization. WHO Three I's Meeting: intensified case finding (ICF), isoniazid preventive therapy (IPT) and TB infection control (IC) for people living with HIV. Report of a Joint World Health Organization HIV/AIDS and TB Department Meeting. Geneva: World Health Organization, 2008; 2-4. http://www.who.int/hiv/pub/meetin-greports/WHO-31s-meeting-report.pdf. Accessed 9 April 2010.
33. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368(9547): 1575-1580. (Pubitemid 44780738)
34. Basu S, Friedland GH, Medlock J, et al. Averting epidemics of extensively drug-resistant tuberculosis. Proc Natl Acad Sci U S A 2009; 106(18):7672-7677.
35. Alonso-Echanove J, Granich RM, Laszlo A, et al. Occupational transmission of Mycobacterium tuberculosis to health care workers in a university hospital in Lima, Peru. Clin Infect Dis 2001;33(5):589-596.
36. Harries AD, Hargreaves NJ, Gausi F, Kwanjana JH, Salaniponi FM. Preventing tuberculosis among health workers in Malawi. Bull World Health Organ 2002;80(7):526-531. (Pubitemid 34826705)
37. World Health Organization. Guidelines for the prevention of tuberculosis among health care workers in resource-limited settings. Geneva: World Health Organization, 1999.
38. World Health Organization. Tuberculosis infection control in the era of expanding HIV care and treatment: addendum to WHO Guidelines for the Prevention of Tuberculosis in Health Care Facilities in ResourceLimited Settings. 2006. http://whqlibdoc.who.int/hq/1999/WHO-TB-99.269-ADD-eng.pdf. Accessed 9 April 2010.
39. Preventive therapy against tuberculosis in people living with HIV. Wkly Epidemiol Rec 1999;74(46):385-398.
40. Foster S, Godfrey-Faussett P, Porter J. Modelling the economic benefits of tuberculosis preventive therapy for people with HIV: The example of Zambia. AIDS 1997; 11(7):919-925. (Pubitemid 27226416)
41. Terris-Prestholt F, Kumaranayake L, Ginwalla R, et al. Integrating tuberculosis and HIV services for people living with HIV: Costs of the Zambian ProTEST Initiative. Cost Eff Resour Alloc 2008; 6:2. (Pubitemid 351386050)
42. World Health Organization. TB/HIV Clinical Manual. Geneva: World Health Organization, 2004.
43. World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. Geneva: World Health Organization, 2006.
44. Geiter LJ, O'Brien RJ. From the Centers for Disease Control. Conference on new approaches for tuberculosis preventive therapy. J Infect Dis 1987; 156(3):536-537.
45. A strategic plan for the elimination of tuberculosis in the United States. MMWR Morb Mortal Wkly Rep 1989;38(16):269-272.
46. Mosimaneotsile B, Talbot EA, Moeti TL, et al. Value of chest radiography in a tuberculosis prevention programme for HIV-infected people, Botswana. Lancet 2003;362(9395):1551-1552. (Pubitemid 37410196)
47. de Pinho AM, Santoro-Lopes G, Harrison LH, Schechter M. Chemoprophylaxis for tuberculosis and survival of HIV-infected patients in Brazil. AIDS 2001; 15(16):2129-2135. (Pubitemid 33101820)
48. Johnson JL, Okwera A, Horn DL, et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS 2001; 15(16):2137-2147. (Pubitemid 33101821)
49. Quigley MA, Mwinga A, Hosp M, et al. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS 2001; 15(2):215-222. (Pubitemid 32142297)
50. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999;3(10):847-850.
51. Mwinga A, Hosp M, Godfrey-Faussett P, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998; 12(18): 2447-2457. (Pubitemid 28558603)
52. UNAIDS. 2007 AIDS epidemic update. UNAIDS Report (2007). 2008. http://data.unaids.org/pub/EPISlides/2007/2007-epiupdate-en.pdf. Accessed 9 April 2010.
53. Jeena PM, Pillay P, Pillay T, Coovadia HM. Impact of HIV-1 co-infection on presentation and hospital-related mortality in children with culture proven pulmonary tuberculosis in Durban, South Africa, Int J Tuberc Lung Dis 2002;6(8):672-678. (Pubitemid 34832146)
54. Chintu C, Mwaba P. Tuberculosis in children with human immunodeficiency virus infection, Int J Tuberc Lung Dis 2005;9(5):477-484. (Pubitemid 40646832)
55. Gray DM, Zar H, Cotton M. Impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children. Cochrane Database Syst Rev 2009(1):CD006418.
56. Hesseling AC, Westra AE, Werschkull H, et al. Outcome of HIV infected children with culture confirmed tuberculosis. Arch Dis Child 2005; 90(11):1171-1174. (Pubitemid 41565280)
57. Palme IB, Gudetta B, Bruchfeld J, Muhe L, Giesecke J. Impact of human immunodeficiency virus 1 infection on clinical presentation, treatment outcome and survival in a cohort of Ethiopian children with tuberculosis. Pediatr Infect Dis J 2002;21(11):1053-1061. (Pubitemid 35334515)
58. Zar HJ, Cotton MF, Strauss S, et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ 2007;334(7585):136. (Pubitemid 46173957)
59. World Health Organization. Report of the meeting on TB medicines for children. Geneva: World Health Organization, July 2008:5. http:// www.who.int/selection-medicines/committees/subcommittee/2/TB.pdf. Accessed 9 April 2010.
60. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ 1982;60(4):555-564.
61. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, GodfreyFaussett P. HIV-1 and recurrence, relapse, and reinfection of tuber- culosis after cure: a cohort study in South African mineworkers. Lancet 2001;358(9294):1687-1693. (Pubitemid 33124328)
62. Churchyard GJ, Fielding K, Charalambous S, et al. Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy? AIDS 2003; 17(14):2063-2070.
63. Fitzgerald DW, Morse MM, Pape JW, Johnson WD Jr. Active tuberculosis in individuals infected with human immunodeficiency virus after isoniazid prophylaxis. Clin Infect Dis 2000;31(6):1495-1497.
64. Fitzgerald DW, Desvarieux M, Severe P, Joseph P, Johnson WD Jr, Pape JW. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. Lancet 2000;356(9240):1470-1474.
65. Girardi E, Sabin CA, d'Arminio Monforte A, et al. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis 2005;41(12):1772-1782.
66. Golub JE, Saraceni V, Cavalcante SC, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2007; 21(11): 1441-1448. (Pubitemid 46988004)
67. Golub JE, Pronyk P, Mohapi L, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS 2009; 23(5):631-636.
68. Lucas SB, Hounnou A, Peacock C, et al. The mortality and pathology of HIV infection in a West African city. AIDS 1993;7(12):1569-1579. (Pubitemid 24008849)
69. Harries AD, Zachariah R, Lawn SD. Providing HIV care for co-infected tuberculosis patients: a perspective from sub-Saharan Africa, Int J Tuberc Lung Dis 2009; 13(1):6-16.
70. Lawn SD, Wilkinson RJ, Lipman MC, Wood R. Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med 2008; 177(7):680-685. (Pubitemid 351490554)
71. Corbett EL, Bandason T, Cheung YB, et al. Epidemiology of tuberculosis in a high HIV prevalence population provided with enhanced diagnosis of symptomatic disease. PLoS Med 2007;4(1):e22. (Pubitemid 46191831)
72. Ayles H, Schaap A, Nota A, et al. Prevalence of tuberculosis, HIV and respiratory symptoms in two Zambian communities: implications for tuberculosis control in the era of HIV. PLoS ONE 2009;4(5):e5602.
73. Mtei L, Matee M, Herfort O, et al. High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis 2005;40(10):1500-1507. (Pubitemid 40628639)
74. Wood R, Middelkoop K, Myer L, et al. Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med 2007; 175(1):87-93. (Pubitemid 46105314)
75. Perlman DC, el-Sadr WM, Nelson ET, et al. Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression. The Terry Beim Community Programs for Clinical Research on AIDS (CPCRA). The AIDS Clinical Trials Group (ACTG). Clin Infect Dis 1997; 25(2): 242-246.
76. Aderaye G, Bruchfeld J, Assefa G, et al. The relationship between disease pattern and disease burden by chest radiography, M. tuberculosis load, and HIV status in patients with pulmonary tuberculosis in Addis Ababa. Infection 2004;32(6):333-338.
77. Day JH, Charalambous S, Fielding KL, Hayes RJ, Churchyard GJ, Grant AD. Screening for tuberculosis prior to isoniazid preventive therapy among HIV-infected gold miners in South Africa, Int J Tuberc Lung Dis 2006; 10(5):523-529. (Pubitemid 43667640)
78. Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis 2006;12(5):744-751. (Pubitemid 43726847)
79. Davies GR, Connolly C, Sturm AW, McAdam KP, Wilkinson D. Twiceweekly, directly observed treatment for HIV-infected and uninfected tuberculosis patients: cohort study in rural South Africa. AIDS 1999; 13(7):811-817. (Pubitemid 29224583)
80. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133(3):423-430. (Pubitemid 16126276)
81. Jones BE, Otaya M, Antoniskis D, et al. A prospective evaluation of antituberculosis therapy in patients with human immunodeficiency virus infection. Am J Respir Crit Care Med 1994; 150(6):1499-1502. (Pubitemid 24978022)
82. Basu S, Maru D, Poolman E, Galvani A. Primary and secondary tuberculosis preventive treatment in HIV clinics: simulating alternative strategies, Int J Tuberc Lung Dis 2009; 13(5):652-658.
83. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999;281(11):1014-1018.
84. Breen RA, Lipman MC, Johnson MA. Increased incidence of peripheral neuropathy with co-administration of stavudine and isoniazid in HIVinfected individuals. AIDS 2000; 14(5):615.
85. LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 2003; 168(4): 443-1147
86. Grant AD, Charalambous S, Fielding KL, et al. Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study. JAMA 2005;293(22):2719-2725. (Pubitemid 40965083)
87. Wright A, Zignol M, Van Deun A, et al. Epidemiology of antituberculosis drug resistance 2002-2007: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 2009;373(9678):1861-1873.
88. Management of persons exposed to multidrug-resistant tuberculosis. MMWR Recomm Rep 1992;41(RR-11):61-71.
89. Chapter 4: childhood contact screening and management, Int J Tuberc Lung Dis 2007; 11(1):12-15.